Oncofetal Fibronectin mRNA Is Highly Abundant in the Blood of Patients with Papillary Thyroid Carcinoma and Correlates with High-Serum Thyroid-Stimulating Hormone Levels

Thyroid ◽  
2010 ◽  
Vol 20 (6) ◽  
pp. 607-613 ◽  
Author(s):  
Michael Wehmeier ◽  
Thorsten Petrich ◽  
Korbinian Brand ◽  
Ralf Lichtinghagen ◽  
Eric Hesse
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Stimulating Hormone ◽  
High Serum ◽  
Papillary Thyroid ◽  
Hormone Levels ◽  
Oncofetal Fibronectin ◽  
Fibronectin Mrna ◽  
Stimulating Hormone

scholarly journals Thyroid Stimulating Hormone Suppression and Recurrence After Thyroid Lobectomy For Papillary Thyroid Carcinoma

2021 ◽  
Author(s):  
Mi Rye Bae ◽  
Sung Hoon Nam ◽  
Jong-Lyel Roh ◽  
Seung-Ho Choi ◽  
Soon Yuhl Nam ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Stimulating Hormone ◽  
American Thyroid Association ◽  
Regression Analyses ◽  
Papillary Thyroid ◽  
Tsh Suppression ◽  
Thyroid Lobectomy ◽  
Stimulating Hormone

Abstract Background Thyroid lobectomy is recommended as the primary treatment for low-risk thyroid cancer. However, recurrence and hypothyroidism may develop after lobectomy, necessitating thyroid hormone supplementation. The 2015 American Thyroid Association (ATA) guidelines recommended post-lobectomy thyroid-stimulating hormone (TSH) suppression. This study examined the need for TSH suppression and recurrence after lobectomy for unilateral papillary thyroid carcinoma (PTC). Methods This study involved 369 patients who underwent thyroid lobectomy and ipsilateral central neck dissection for PTC between 2007 and 2015. Thyroid function tests were performed before and regularly after lobectomy. Binary logistic regression analyses were used to find factors predictive of the post-lobectomy need for TSH suppression that was defined by the 2015 ATA guidelines. Results Serum TSH concentrations gradually increased after lobectomy: proportions with TSH > 2 mIU/L at post-lobectomy 1, 3 ~ 6, 12, and 24 months were found in 77.0%, 82.3%, 66.7%, and 59.9%, respectively. After lobectomy, 168 (45.5%) patients received levothyroxine (T4) supplementation. Multivariate logistic regression analyses showed that pre-TSH level > 2 mIU/L was the sole independent variable predictive of the need for post-lobectomy TSH suppression (P = 0.003). During the median follow-up of 72 months, recurrence was found in 4 (1.1%) patients who never received T4 supplementation and had post-lobectomy TSH levels > 2 mIU/L. Conclusions Our data show that thyroid lobectomy for unilateral PTC is associated with a low recurrence rate, but a significant risk of hypothyroidism. Preoperative TSH level can predict the need for post-lobectomy TSH suppression compliant with the 2015 ATA guidelines.

scholarly journals Simultaneous Coexistence of Thyrotropin-Prolactin-Secreting Adenoma and Papillary Thyroid Carcinoma

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Somaya Safi ◽  
Yousra Benabdelfedil ◽  
Sara Derrou ◽  
Faycal El Guendouz
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Complete Response ◽  
Thyroid Stimulating Hormone ◽  
Suppressive Therapy ◽  
Papillary Thyroid ◽  
Case Presentation ◽  
Moroccan Woman ◽  
Potential Link ◽  
Concurrent Case

Background. The thyrotropin-secreting adenomas are very rare and even more rare when they simultaneously coexist with thyroid carcinoma. So far, only sixteen cases have been reported in the literature. Here, we present a unique case of successful management of a concurrent case of thyrotropin-prolactinoma with papillary thyroid carcinoma. Case Presentation. A 50-year-old Moroccan woman underwent a total thyroidectomy and complementary totalization by iratherapy for papillary thyroid carcinoma, who presented persistence of an inappropriate secretion of the thyroid-stimulating hormone (TSH > 4 mUI/L) despite of levothyroxine suppressive therapy (300 μg/d). After eliminating noncompliance, interfering medicines, and thyroid malabsorption, a pituitary adenoma (12 mm) was documented at magnetic resonance imaging. The patient has had transsphenoidal pituitary adenomectomy with histology confirming a thyrotropin-prolactin-secreting adenoma. After surgery and lanreotide treatment failures, we noted a complete response (TSH < 0.5) with cabergoline treatment (3 mg/week). Conclusion. The unusual association of thyroid adenocarcinoma and TSHoma enriches the hypothesis of a potential link between thyrotropic hypersecretion and thyroid carcinogenesis. Our case also illustrates the difficulty of monitoring thyroid carcinoma in nonremission of a TSHoma.

Sign in / Sign up

Export Citation Format

Share Document